Serum neurofilament light chain does not detect self‐reported treatment‐related fluctuations in chronic inflammatory demyelinating polyneuropathy

Abstract

AbstractIntroductionSerum neurofilament light chain (sNfL) is a marker for axonal degeneration. Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) often report a fluctuation of symptoms throughout one treatment cycle with intravenous immunoglobulins (IVIG). The aim of this study was to determine whether sNfL is suitable to quantify patient‐reported symptom fluctuations.MethodsTwenty‐nine patients with the diagnosis of CIDP or a CIDP‐variant under treatment with IVIG were recruited in this study and underwent examination before IVIG infusion, in the middle of the treatment interval, and before their next IVIG infusion. Patients were surveyed regarding symptom fluctuations at the last visit and divided into two groups: those with and without fluctuations of symptoms. At the first visit, sociodemographic and disease‐specific data were collected. Clinical scores were assessed at every examination. sNfL values were compared between both groups at the different time points after conversion into Z‐scores—adjusted for age and body mass index.ResultsPatients with CIDP show elevated sNfL Z‐scores (median at baseline: 2.14, IQR: 1.0). There was no significant change in sNfL Z‐scores or questionnaire scores within the treatment cycle in either group. There was no significant difference in sNfL levels between the patients with and without symptom fluctuations.ConclusionsCIDP patients show elevated sNfL levels. However, sNfL is not suitable to reflect patient‐reported fluctuations of symptoms. This indicates that symptom fluctuations during treatment with IVIG in patients with CIDP are not caused by a neuroaxonal injury. Furthermore, repeated sNfL measurements within one treatment cycle with IVIG seem to have no benefit for symptom monitoring.